
Researchers at the Schepens Eye Research Institute have developed a promising strategy for glaucoma cell replacement therapy, a leading cause of global blindness. They altered the eye's micro-environment to convert blood stem cells into retinal ganglion cells (RGCs), crucial for vision. Unlike existing methods where donor cells often remain in the injection site, this technique enabled RGCs to migrate and survive in the retina. By identifying stromal-derived factor 1 as an effective chemokine, the researchers demonstrated a potential breakthrough for restoring vision in glaucoma patients.
Like
Save
Share